Product Images Dayvigo

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 11 images provide visual information about the product associated with Dayvigo NDC 62856-410 by Eisai Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

The structural formula for DAYVIGO contains lemborexant, an orexin receptor antagonist. The chemical name of lemborexant is (1R,2S)-2-{[(2,4-dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl) cyclopropanecarboxamide. The molecular formula is C22H20F2N4O2. The molecular weight is 410.42. - dayvigo 01

Figure 1. Effects of Hepatic and Renal Impairment on Lemborexant Pharmacokinetics - dayvigo 02

The text appears to be a graph or table displaying fold change and confidence intervals for hepatic and renal impairment. There is not enough information to provide a detailed description.*

Figure 2. Effects of Co-administered Drugs on the Pharmacokinetics of Lemborexant 10 mg - dayvigo 03

Figure 3. Effects of Lemborexant 10 mg on the Pharmacokinetics of Co-Administered Drugs - dayvigo 04

This is a report on drug interaction based on changes and confidence intervals for CYP286 substrate. The report provides fold change values for various drugs including Supropon, Buaropon, VPR Subate, and Mazoiam, with respect to reference. The report also includes a graph showing changes in Auc (area under the curve) for Noratesione.*

PRINCIPAL DISPLAY PANELNDC 62856-405-30DAYVIGO(lemborexant) tablets5 mg30 Tablets - dayvigo 05

PRINCIPAL DISPLAY PANELNDC 62856-405-90DAYVIGO(lemborexant) tablets5 mg90 Tablets - dayvigo 06

This is a pharmaceutical label for a medication called "lemborexant". The label shows the dosage information and the prescription details for the medication. It also indicates the recommended temperature to store the medication and the precautions to take. The medication should be kept in a child-resistant container. The accompanying medication guide is also provided to the patient. No further information is available due to the limited text and lack of context.*

PRINCIPAL DISPLAY PANELNDC 62856-410-30DAYVIGO(lemborexant) tablets10 mg30 Tablets - dayvigo 07

DAYVIGO is a medication that comes in tablet form and should be stored within the recommended temperature range, as detailed in the packaging. It should also be kept out of reach of children and dispensed in a chi-resistant container. The medication guide should be provided to the patient when dispensing this prescription-only medication. There is no information about the usual dosage, and the text includes a product code and the name of the manufacturer.*

PRINCIPAL DISPLAY PANELNDC 62856-410-90DAYVIGO(lemborexant) tablets10 mg90 Tablets - dayvigo 08

DAYVIGO is a medication that comes in the form of tablets. The usual dosage should be checked on the package insert for prescribing information. The storage temperature is between 20°C to 25°C, with excursions allowed between 15°C to 30°C. It is important to keep DAYVIGO out of the reach of children and dispensed in a child-resistant container. The medication guide must be given to the patient along with the medication. The text includes a product code of NDC 62856-410-90 and indicates that the medication is for prescription-only. There is no information about the drug's usage or effects.*

dayvigo 09

dayvigo 0a

dayvigo 0b

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.